Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries

USA - English

• USA - Français
• USA - Deutsch

NEW YORK, January 11, 2019 /PRNewswire/ --

Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, and IDEA Pharma Ltd (a UK-based path-to-market strategy and applied innovation consulting group), have announced a highly original partnership, to bring together Amarantus' innovative therapeutics and diagnostics portfolio with IDEA's industry-leading path-to-market expertise. IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model. The virtual Chief Commercial Officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation. The Amarantus/ IDEA Pharma partnership will run for 5 years, and be renewable upon mutual consent.

"The Amarantus portfolio is exciting and innovative, and we were keen to match that innovation with a model that incentivises successful commercialisation," said Mike Rea, CEO IDEA Pharma. "The traditional fee-for-service consulting model is one that rewards quantity of input over quality, and imports established ideas from large pharma. When you win together it drives the best behaviour and crucially, allows an early-stage company like Amarantus to benefit from the right strategic inputs early. We are especially excited about working with the organizations being established around each of Amarantus' pipeline products as we will be able to create value for Amarantus not only with its portfolio, but also with the complementary assets being aggregated within each of those organizations, beginning with Coeptis' recently approved product Consensi®."

"One of the key challenges for an early-stage biotech is to combine agility and innovation with world-class expertise, and the reassurance of experience," said Gerald Commissiong, CEO Amarantus. "A key area of focus for Amarantus is to maximize leading commercial competency that can both answer the 'what if' questions quickly and correctly - minimising cost, but maximising returns. This partnership will bring our subsidiaries cutting edge understanding of Commercial, incentivised for the long-term, which is hard to achieve in a traditional hiring strategy, or with fee-for-service partners. We believe this is the perfect blend of risk mitigation with maximisation of upside, and importantly for a biotech, we keep subsidiary overhead to a minimum."

About Amarantus Bioscience Holdings, Inc. 

Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders and Parkinson's dsiease. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. The Company also owns certain rights to the Alzheimer's blood diagnostic LymPro Test ®, as well as MSPrecise™ and NuroPro.

For further information please visit http://www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.

Amarantus Investor and Media Contact:
Gerald Commissiong
Office: +1-650-862-5391
Email: [email protected]

IDEA Pharma Media Contact:
Mike Rea
Office: +44-1234-756-340
Email: [email protected]

SOURCE Amarantus Bioscience Holdings, Inc.